Stock News & Analysis

Dividend stocks generate passive income even when the market is falling.

ONCE Capital increased its stake in NuScale Power during the fourth quarter as AI-driven data centers boost demand for reliable electricity. NuScale is developing small modular nuclear reactors designed to provide steady, around-the-clock power. Investors will be watching whether the company can turn that vision into fully funded projects and measurable progress.

This fixed income ETF targets short-term bonds, balancing yield and liquidity for investors seeking core portfolio stability.

It's been quite the day for risk assets, and the world's largest meme coin is clearly feeling it.

Signet Jewelers has seen its stock jump in value nearly 92% over the past 12 months.

Oddity's valuation is getting crushed following the company's latest earnings report.

Is the stock ready for another breakout?

Structure Therapeutics develops oral drugs for chronic diseases, with lead assets targeting diabetes, obesity, and cardiovascular care.

The new 15% "global" tariff replaces the discontinued "Liberation Day" tariffs.

The advent of artificial intelligence is about to be bottlenecked in a big way most investors have yet to notice.

This biotech innovator develops peptide-based therapies for blood and immune disorders, advancing a pipeline of clinical-stage candidates.

His latest SEC filing reveals that the venture capitalist's hedge fund sold its entire stock portfolio last quarter.

BAMCO trimmed its position in Vail Resorts as Epic Pass sales set up the winter season. Vail runs a large portfolio of destination resorts, and investors will be watching whether traffic and guest spending will support the company's earnings outlook.

This U.S. telecom and technology provider reported a notable insider sale amid a year of significant share price movement.

Disc Medicine develops therapies for rare blood disorders, leveraging clinical-stage biotech expertise in red blood cell biology.

Don't rush to buy the dip on these popular quantum computing stocks.

This biotech specializes in monoclonal antibody therapies for inflammatory and immunological diseases with significant unmet needs.

There were a couple of unusual factors weighing on Ford's fourth-quarter results. Here's what investors need to know.

Broadcom is one of the most balanced AI stocks to buy in 2026.

RAPT Therapeutics develops oral therapies for oncology and inflammatory diseases, with lead candidates progressing in clinical trials.